Stockscreener 앱 받기
1.53
7.83%
-0.13
전일 마감가:
$1.66
열려 있는:
$1.65
하루 거래량:
1.78M
Relative Volume:
0.49
시가총액:
$6.16M
수익:
-
순이익/손실:
$-8.22M
주가수익비율:
-0.0559
EPS:
-27.3467
순현금흐름:
$-8.01M
1주 성능:
-15.00%
1개월 성능:
-39.29%
6개월 성능:
-71.82%
1년 성능:
-89.72%
1일 변동 폭
$1.50
$1.69
1주일 범위
$1.50
$1.90
52주 변동 폭
$1.50
$17.64
엔버릭 바이오 Stock (ENVB) Company Profile
명칭
Enveric Biosciences Inc
전화
(617) 444-8400
주소
245 FIRST STREET RIVERVIEW II 18TH FLOOR, CAMBRIDGE
Compare ENVB vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ENVB
Enveric Biosciences Inc
|
1.53 | 6.16M | 0 | -8.22M | -8.01M | -27.35 |
VRTX
Vertex Pharmaceuticals Inc
|
444.93 | 112.92B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
612.14 | 64.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
893.52 | 55.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.85 | 37.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.87 | 32.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
엔버릭 바이오 주식(ENVB)의 최신 뉴스
ENVB SEC FilingsEnveric Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Enveric Biosciences Expands At-The-Market Equity Offering - TipRanks
Enveric Biosciences (NASDAQ: ENVB) expands $2.4M at-the-market stock program - Stock Titan
Enveric Biosciences (ENVB) amends ATM; $2.425M remaining capacity - Stock Titan
Enveric Biosciences to Participate in the UBS 3rd Virtual CNS Day - Investing News Network
Enveric's High-Stakes Pitch: Selling Neuroplasticity Without the Trip - BriefGlance
Enveric Biosciences Releases Updated Investor Presentation Materials - TipRanks
Enveric Biosciences posts investor presentation on website under Regulation FD - TradingView
Enveric Biosciences (NASDAQ: ENVB) furnishes Q2 2026 investor presentation - Stock Titan
Enveric Biosciences Announces Withdrawal Of Petition Against Its Patent — ENVB Stock Rises - Stocktwits
ENVB Stock Chart | ENVERIC BIOSCIENCES INC (NASDAQ:ENVB) - ChartMill
[Form 4] Enveric Biosciences, Inc. Insider Trading Activity - Stock Titan
Enveric Biosciences (ENVB) CFO awarded 133,333 RSUs in long-term equity grant - Stock Titan
Enveric Biosciences (ENVB) CEO granted 201,124 RSUs under 2020 long-term plan - Stock Titan
Enveric Biosciences (ENVB) director receives 18,518 restricted stock shares as equity grant - Stock Titan
Director at Enveric Biosciences (ENVB) receives 18,518 restricted shares - Stock Titan
Enveric (ENVB) awards director Marcus Schabacker 18,518 restricted shares - Stock Titan
Enveric Biosciences (ENVB) awards 25,000 RSUs to its CIO - Stock Titan
Enveric Biosciences (ENVB) Launches Critical Safety Studies for EB-003 - GuruFocus
Enveric Biosciences Initiates Investigational New Drug -enabling Genotoxicity Studies of Lead Neuroplastogen Candidate EB-003 - Investing News Network
Enveric Biosciences stock rises on genotoxicity study launch By Investing.com - Investing.com India
Enveric Biosciences stock rises on genotoxicity study launch - Investing.com
Enveric Biosciences begins genotoxicity studies for EB-003 - Investing.com
Enveric Biosciences begins genotoxicity studies for EB-003 By Investing.com - Investing.com Canada
Enveric Biosciences Initiates Investigational New Drug (IND)-enabling Genotoxicity Studies of Lead Neuroplastogen Candidate EB-003 - Business Wire
Enveric Biosciences (NASDAQ: ENVB) holders OK reverse split, block share increase - Stock Titan
Enveric Biosciences Holds Near Support Amid Modest PullbackPCR Moving Average - thelegaladvocate.com
ENVB Technical Analysis | Trend, Signals & Chart Patterns | ENVERIC BIOSCIENCES INC (NASDAQ:ENVB) - ChartMill
Enveric Biosciences Inc Annual Shareholders Meeting Transcript - GuruFocus
ENVB Stock Price, Quote & Chart | ENVERIC BIOSCIENCES INC (NASDAQ:ENVB) - ChartMill
Enveric Biosciences Company Profile & Introduction - Moomoo
Enveric Biosciences Inc. (ENVB) Q4 2024 Earnings: Massive EPS Miss Highlights Ongoing Cash Burn and No Revenue - thelegaladvocate.com
Enveric Biosciences (ENVB) Achieves Key Milestone in Neuropsychi - GuruFocus
Enveric Biosciences Reports Positive Preclinical Results from Phototoxicity Analysis for Lead Neuroplastogen Candidate EB-003 - Investing News Network
Enveric Biosciences Reports Financial Results and Provides Corporate Update for First Quarter 2026 - BioSpace
Enveric Biosciences 1Q Loss/Shr $1.08 >ENVB - Moomoo
Enveric Biosciences Inc (ENVB) Stock Price, Quote, News & History - Benzinga
Enveric Biosciences (ENVB) affiliates report 158,732 warrants; Easton 161,232 - Stock Titan
Enveric (ENVB) Secures $13.9 Million in Private Placement Fundin - GuruFocus
Enveric (ENVB) Advances in Mental Health Therapeutics Developmen - GuruFocus
Enveric Biosciences Reports Q1 2026 Results, Advances Non-Hallucinogenic Antidepressant EB-003 Toward Clinical Trials - Minichart
Enveric Biosciences Releases Q1 2026 Financial Results - AlphaStreet
Enveric Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Enveric Biosciences (NASDAQ: ENVB) posts Q1 2026 loss and flags going concern risk - Stock Titan
Enveric Biosciences (ENVB) advances EB-003 and boosts cash in Q1 2026 - Stock Titan
What's going on with Enveric Biosciences stock on Friday? - MSN
Enveric Biosciences Expands IP Portfolio with New U.S. Patent Issued for Methods of Treating Psychiatric Disorders - Investing News Network
Enveric highlights preclinical PTSD data amid rising focus on mental health therapies - MSN
Enveric Biosciences receives patent for psilocybin derivatives By Investing.com - Investing.com Canada
Enveric Biosciences Stock Short Interest Rises to 45.7% - Moomoo
엔버릭 바이오 (ENVB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.04%
0.76%
자본화:
|
볼륨(24시간):